Citation Impact
Citing Papers
Characterization of Functional Excision Repair Cross-Complementation Group 1 Variants and Their Association with Lung Cancer Risk and Prognosis
2008
Cell Adhesion Molecules, Vascular Endothelial Growth Factor, and Basic Fibroblast Growth Factor in Patients with Non–Small Cell Lung Cancer Treated with Chemotherapy with or without Bevacizumab—an Eastern Cooperative Oncology Group Study
2008
2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer
2015 Standout
Hypoxia — a key regulatory factor in tumour growth
2002 Standout
First-line chemotherapy for NSCLC: an overview of relevant trials
2002
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
2017 Standout
EGFR Antagonists in Cancer Treatment
2008 Standout
Combined Vemurafenib and Cobimetinib in BRAF -Mutated Melanoma
2014 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Therapeutic cancer vaccines: are we there yet?
2010
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
2015 Standout
Chemotherapy for small cell lung cancer
2003
Increased Survival with Enzalutamide in Prostate Cancer after Chemotherapy
2012 Standout
Gefitinib or Carboplatin–Paclitaxel in Pulmonary Adenocarcinoma
2009 Standout
The biology and management of non-small cell lung cancer
2018 StandoutNature
Paraneoplastic Syndromes Involving the Nervous System
2003 Standout
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
2014 Standout
Neurologic disorders in 432 consecutive patients with small cell lung carcinoma
2004
Lung Cancer
2008 Standout
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
2008 Standout
Identification of the transforming EML4–ALK fusion gene in non-small-cell lung cancer
2007 StandoutNature
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
2006 Standout
Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer
2004
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis
2004
Early Palliative Care for Patients with Metastatic Non–Small-Cell Lung Cancer
2010 Standout
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer
2014 StandoutNature
New Cisplatin Analogues in Development
1993
Lung cancer: current therapies and new targeted treatments
2016 Standout
Global cancer statistics
2011 Standout
Prediction of neurological outcome after cardiopulmonary resuscitation by serial determination of serum neuron-specific enolase
2006
The International Epidemiology of Lung Cancer: Geographical Distribution and Secular Trends
2008
Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial
2016 Standout
EGFR Mutation and Resistance of Non–Small-Cell Lung Cancer to Gefitinib
2005 Standout
Paclitaxel and carboplatin in combination in the treatment of advanced non-small-cell lung cancer: a phase II toxicity, response, and survival analysis.
1995
Chemotherapy as treatment of primary and recurrent small cell lung cancer
2001
Lenvatinib versus Placebo in Radioiodine-Refractory Thyroid Cancer
2015 Standout
Mitochondrial Membrane Permeabilization in Cell Death
2007 Standout
Randomized Study of Maintenance Vinorelbine in Responders With Advanced Non-Small-Cell Lung Cancer
2005
Evaluation of cisplatin intensity in metastatic non-small-cell lung cancer: a phase III study of the Southwest Oncology Group.
1993
MicroRNA signatures in human cancers
2006 Standout
Microtubules as a target for anticancer drugs
2004 Standout
Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)
2005 Standout
Palbociclib and Letrozole in Advanced Breast Cancer
2016 Standout
Small-cell lung cancer
2005
HLA and smoking in prediction and prognosis of small cell lung cancer in autoimmune Lambert–Eaton myasthenic syndrome
2004
Systemic Inflammatory Response Predicts Prognosis in Patients with Advanced-Stage Colorectal Cancer
2008
Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
2002 Standout
Erlotinib in Lung Cancer — Molecular and Clinical Predictors of Outcome
2005 Standout
Platinum-Based Chemotherapy plus Cetuximab in Head and Neck Cancer
2008 Standout
Eribulin versus dacarbazine in previously treated patients with advanced liposarcoma or leiomyosarcoma: a randomised, open-label, multicentre, phase 3 trial
2016 Standout
Anemia of Chronic Disease
2005 Standout
Hepatocellular carcinoma
2022 Standout
Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
2004 Standout
Carboplatin versus cisplatin in solid tumors: An analysis of the literature
1998
Pembrolizumab versus Chemotherapy for PD-L1–Positive Non–Small-Cell Lung Cancer
2016 Standout
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity
2006
The Next Generation of Platinum Drugs: Targeted Pt(II) Agents, Nanoparticle Delivery, and Pt(IV) Prodrugs
2016 Standout
Biochemical Modulation of Cisplatin Mechanisms of Action: Enhancement of Antitumor Activity and Circumvention of Drug Resistance
2003 Standout
Phase III Trial of Gemcitabine Plus Cisplatin Versus Cisplatin Alone in Patients With Locally Advanced or Metastatic Non–Small-Cell Lung Cancer
2000
Tirapazamine Plus Cisplatin Versus Cisplatin in Advanced Non–Small-Cell Lung Cancer: A Report of the International CATAPULT I Study Group
2000
Adoptive cell transfer as personalized immunotherapy for human cancer
2015 StandoutScience
Review of Phase II Trial Designs Used in Studies of Molecular Targeted Agents: Outcomes and Predictors of Success in Phase III
2008
Current Status of Platinum-Based Antitumor Drugs
1999 Standout
Chemotherapy of advanced non-small cell lung cancer
1999
Cancer statistics in China, 2015
2016 Standout
Part 9: Post–Cardiac Arrest Care
2010 Standout
Serum S-100 and Neuron-Specific Enolase for Prediction of Regaining Consciousness After Global Cerebral Ischemia
1998
Structure, Recognition, and Processing of Cisplatin−DNA Adducts
1999 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
mice: Multivariate Imputation by Chained Equations inR
2011 Standout
Gemcitabine/carboplatin combination regimens: importance of dose schedule.
2000
Objective Responses in Patients with Malignant Melanoma or Renal Cell Cancer in Early Clinical Studies Do Not Predict Regulatory Approval
2005
New Perspectives on an Old Friend: Optimizing Carboplatin for the Treatment of Solid Tumors
1998
Global cancer statistics, 2012
2015 Standout
Randomized Phase III Trial of Paclitaxel Plus Carboplatin Versus Vinorelbine Plus Cisplatin in the Treatment of Patients With Advanced Non–Small-Cell Lung Cancer: A Southwest Oncology Group Trial
2001
Works of G. Bureau being referenced
Randomized trial comparing induction chemotherapy versus induction chemotherapy followed by maintenance chemotherapy in small-cell lung cancer. European Lung Cancer Working Party.
1996
Phase III randomized trial comparing cisplatin and carboplatin with or without ifosfamide in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1998
A randomized study comparing cisplatin or carboplatin with etoposide in patients with advanced non-small-cell lung cancer: European Organization for Research and Treatment of Cancer Protocol 07861.
1990
Prognostic factors for survival in advanced non-small-cell lung cancer: univariate and multivariate analyses including recursive partitioning and amalgamation algorithms in 1,052 patients. The European Lung Cancer Working Party.
1995
Cisplatin versus cisplatin plus etoposide in the treatment of advanced non-small-cell lung cancer. Lung Cancer Working Party, Belgium.
1989
Prognostic factors for patients with small cell lung carcinoma
2000
Response to chemotherapy has predictive value for further survival of patients with advanced non-small cell lung cancer: 10 years experience of the european lung cancer working party
1997
A randomized trial comparing in small cell lung cancer (SCLC) induction chemotherapy by ifosfamide and etoposide with adriamycin (IVA) or epirubicine (IVE): An European lung cancer working party report
1993
Phase II randomized trial comparing high-dose cisplatin with moderate-dose cisplatin and carboplatin in patients with advanced non-small-cell lung cancer. European Lung Cancer Working Party.
1994
Monoclonal Immunoradiometric Assay and Polyclonal Radioimmunoassay Compared for Measuring Neuron-Specific Enolase in Patients with Lung Cancer
1992